Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3185643 (Part B)
LY3185643 · 1 trial · 1 indication
Maximum observed plasma concentration (Cmax) was assessed for LY3185643 and rGlucagon.
Area under the concentration versus time curve from zero to infinity (AUC0-inf) was assessed for LY3185643 and rGlucagon.
Cmax was assessed for LY3185643 and rGlucagon.
Cmax was assessed for C-peptide of LY3185643 and rGlucagon
Area under the concentration versus time curve from time zero to 3 hours \[AUC (0-3)\] was assessed for LY3185643 and rGlucagon.
Area under the concentration versus time curve from time zero to 3 hours \[AUC (0-3)\] was assessed for C-peptide of LY3185643 and rGlucagon.
| Arm | Type | Description |
|---|---|---|
| LY3185643 | EXPERIMENTAL | LY3185643 administered subcutaneous (SC) |
| rGlucagon | EXPERIMENTAL | rGlucagon administered subcutaneous (SC) |
| Name | Type | Description |
|---|---|---|
| LY3185643 | DRUG | Administered SC |
| rGlucagon | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy as determined by medical history and physical examination * Body mass index of 18.0 to 30.0 kilograms per square meter (kg/m²) Exclusion Criteria: * Have participated, within the last 30 days, in a clinical trial involving an investigational product * Kno...
LY3185643 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy participants, and its specific therapeutic indication has not been disclosed. The compound is also referred to as LY3185643 (Part B) in study documentation.
LY3185643 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound in healthy participants conducted in Singapore.
LY3185643 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study was randomized, double-blind, and controlled, and it enrolled 23 healthy participants.
LY3185643 has been evaluated in one completed Phase 1 trial, NCT02951780, titled A Study of LY3185643 and rGlucagon in Healthy Participants. The trial enrolled 23 healthy volunteers in Singapore, included participants aged 21 years and older of all sexes, and used a randomized, double-blind, controlled design.
Yes. LY3185643 (Part B) is an alternative designation for LY3185643, the small molecule developed by Eli Lilly and Company. Both names refer to the same investigational compound studied in the Phase 1 trial NCT02951780.